반려동물 건강 시장 규모, 점유율, 동향 및 예측 : 동물종, 제품 유형, 최종사용자, 지역별(2026-2034년)

The global companion animal health market size was valued at USD 29.37 Billion in 2025. Looking forward, IMARC Group estimates the market to reach USD 59.37 Billion by 2034, exhibiting a CAGR of 7.03% from 2026-2034. North America currently dominates the market, holding a market share of 40.5% in 2025. The region benefits from high pet ownership rates, advanced veterinary infrastructure, widespread pet insurance adoption, and robust government support for animal healthcare standards, which collectively sustain strong demand and underpin the companion animal health market share.

The global companion animal health market is experiencing robust growth driven by a convergence of demographic, economic, and scientific factors. The increasing trend of pet humanization has fundamentally transformed how owners approach animal healthcare, with more individuals treating companion animals as family members and seeking premium medical services. Rising disposable incomes across both developed and emerging economies have expanded the willingness to invest in preventive care, diagnostics, and specialized treatments. Growing awareness of zoonotic diseases has further reinforced the importance of regular veterinary care and vaccination programs. Technological advancements in veterinary diagnostics, including point-of-care testing devices and advanced imaging systems, are enabling earlier and more accurate disease detection. The expansion of veterinary telemedicine services has improved accessibility to healthcare advice in underserved regions. Additionally, the surge in pet adoption, particularly during and after the global pandemic period, has structurally increased the companion animal population, thereby creating a sustained and expanding base of demand for health products and services, reflecting favorable companion animal health market growth prospects globally.

The United States has emerged as a major region in the companion animal health market owing to many factors. The country hosts one of the largest companion animal populations in the world, with pets present in millions of households across urban and rural settings. An extensive network of licensed veterinary clinics, animal hospitals, and specialty care centers forms a strong foundation for service delivery. Federal oversight through agencies such as the US Department of Agriculture and the Food and Drug Administration ensures rigorous standards for pharmaceutical approvals and veterinary product safety. The widespread availability of pet insurance coverage has made advanced treatments financially accessible to a broader segment of pet owners, encouraging more frequent veterinary visits and uptake of specialized therapies. Research and development investments in novel biologics and targeted therapeutics are particularly strong within the country.

COMPANION ANIMAL HEALTH MARKET TRENDS:

Surge in Pet Insurance Adoption

The rising uptake of pet insurance across major markets is significantly reshaping how companion animal healthcare is financed and accessed. As veterinary costs for complex procedures and chronic disease management continue to escalate, more pet owners are turning to insurance plans to manage unexpected medical expenses. This shift is encouraging higher utilization of advanced diagnostics, surgical interventions, and specialist consultations that might otherwise be foregone due to cost constraints. Insurers are increasingly tailoring products to cover a broad range of conditions, from hereditary disorders to dental care and behavioral therapy. The expansion of employer-sponsored pet insurance benefits in North America and parts of Europe has further accelerated enrollment among working-age adults. Technological platforms enabling seamless claims management and policy comparison have lowered barriers to insurance uptake.

Advancements in Veterinary Biologics

The veterinary biologics segment is undergoing a period of rapid scientific advancement, driven by increased research investment and the application of biotechnology platforms to animal health. Novel vaccine formulations leveraging messenger RNA technology are being explored for companion animals, building on methodologies validated during human healthcare applications. Monoclonal antibody therapies have entered the veterinary therapeutics space, offering targeted treatment options for conditions such as allergic dermatitis and osteoarthritis in dogs and cats. These therapies offer compelling advantages over traditional pharmaceuticals, including high specificity, favorable safety profiles, and sustained duration of action. Regulatory agencies in North America and Europe have streamlined approval pathways for priority veterinary biologics, reducing time-to-market for innovative products. Academic-industry collaborations are accelerating the translation of research into commercially viable solutions. The growing pipeline of veterinary biologics reflects broader investment confidence, with major global animal health companies allocating substantial R&D budgets to this area. This trajectory signals a meaningful evolution in treatment paradigms, reflecting positive companion animal health market outlook for the biologics subsegment in the near term.

Expanding Veterinary Telehealth Services

Veterinary telehealth has emerged as a transformative channel within companion animal healthcare, bridging geographic and economic access gaps while enhancing the efficiency of care delivery. Digital platforms connecting pet owners with licensed veterinarians via video consultation, chat, and asynchronous messaging have proliferated following the accelerated digital adoption trends observed in recent years. These services are particularly valuable for initial triage, post-operative monitoring, prescription management, and behavioral consultations, reducing the need for in-person visits for non-emergency cases. The integration of wearable health monitoring devices for pets, capable of tracking vital signs, activity levels, and sleep patterns, is enabling data-driven remote health assessments. Veterinary practices are increasingly adopting hybrid care models that combine in-clinic services with digital touchpoints to improve client engagement and treatment compliance. Regulatory frameworks governing telehealth in veterinary medicine are maturing across key markets, providing greater operational clarity for practitioners and technology providers alike. Growing investment in purpose-built veterinary telehealth infrastructure, including AI-assisted triage tools and cloud-based medical record integration, is further accelerating platform sophistication and scalability. This reflects compelling companion animal health market forecast potential for telehealth-enabled care models globally.

COMPANION ANIMAL HEALTH INDUSTRY SEGMENTATION:

Analysis by Animal Type:

• Dogs
• Cats
• Equine
• Others

Dogs hold 45.0% of the market share. Dogs represent the largest animal type segment within the companion animal health market, reflecting their status as the most widely owned pet species globally. The deep emotional bonds formed between dogs and their owners drive significant spending on preventive care, vaccinations, diagnostics, and treatment of chronic conditions such as arthritis, dermatological disorders, and diabetes. The sheer diversity of dog breeds, each with distinct health predispositions, creates strong demand for a wide array of specialized pharmaceutical and biological products. Growing awareness of preventive wellness programs, including regular screenings and parasite control, has further elevated healthcare engagement among dog owners. The aging dog population in developed markets is contributing to rising demand for senior-specific health solutions, including joint supplements, pain management therapies, and oncology treatments. Furthermore, the premiumization trend in pet care has led owners to seek high-quality, evidence-based medical interventions for their dogs, sustaining consistent revenue growth within this segment and reinforcing its dominant position across the companion animal health industry worldwide.

Analysis by Product:

• Vaccines
• Pharmaceuticals
• Feed Additives
• Diagnostics
• Others

Pharmaceuticals lead the market with a share of 41.0%. Pharmaceuticals represent the cornerstone of companion animal health management, encompassing a broad range of prescription and over-the-counter drugs designed to prevent, treat, and manage diseases across multiple species. The category includes anti-infectives, anti-parasitics, analgesics, anti-inflammatory agents, dermatological preparations, and endocrine therapies, among others. The growing incidence of lifestyle-related conditions in companion animals, including obesity, diabetes, and cardiovascular disorders linked to sedentary environments and processed diets, has amplified pharmaceutical demand. Enhanced regulatory clarity around veterinary drug approvals has facilitated the entry of new formulations with improved efficacy and safety profiles. The development of species-specific dosage forms and palatability-optimized delivery systems has improved owner compliance and treatment adherence. Expansion into novel therapeutic areas, including oncology, neurology, and immunology, reflects the broadening scope of veterinary pharmaceuticals. Continued investment in generic drug development is also improving affordability and access across diverse economic settings, further solidifying pharmaceuticals as the leading product category in the market.

Analysis by End User:

• Point-of-care Testing/In-house Testing
• Veterinary Hospitals and Clinics
• Others

Veterinary hospitals and clinics dominate the market, with a share of 79.8%. These establishments serve as the primary point of contact between companion animals and professional healthcare services, offering comprehensive diagnostic, therapeutic, and surgical capabilities under one roof. The concentration of advanced medical equipment, specialized staff, and established regulatory compliance standards within these settings makes them the preferred channel for complex health interventions, emergency care, and specialist referrals. Rising pet ownership and the growing willingness of owners to invest in preventive wellness programs have translated into higher foot traffic at veterinary facilities worldwide. The ongoing expansion of corporate veterinary chains and multi-specialty animal hospitals across North America, Europe, and Asia-Pacific has enhanced service capacity and standardization. Veterinary hospitals also serve as key distribution points for prescription pharmaceuticals, vaccines, and therapeutic diets, reinforcing their centrality in the health product supply chain. The growing integration of digital tools for appointment scheduling, electronic medical records, and remote monitoring within clinical settings is further strengthening their operational efficiency and competitive position.

Regional Analysis:

• North America
  • United States
  • Canada
• Asia-Pacific
  • China
  • Japan
  • India
  • South Korea
  • Australia
  • Indonesia
  • Others
• Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Russia
  • Others
• Latin America
  • Brazil
  • Mexico
  • Others
• Middle East and Africa

North America, accounting for 40.5% of the share, holds the leading position in the market. The dominance is further fueled by the exceptionally high pet ownership rate in the region, with a considerable number of households in the United States and Canadian territories boasting the presence of companion animals. The presence of thousands of licensed veterinary clinics, specialty hospitals, and emergency care facilities ensures the provision of top-notch health management services to companion animals in the region. The robust institutional frameworks in place to guide the approval of veterinary products and the management of animal welfare add to the dominance of North America in the companion animal health management industry. The pet insurance culture has increased the affordability of top-notch medical services to pets, allowing for the increased use of diagnostics, specialty treatments, and high-end pharmaceutical products. The high level of consumer expenditure in the companion animal health and wellness industry is a reflection of the culture in the region.

KEY REGIONAL TAKEAWAYS:

UNITED STATES COMPANION ANIMAL HEALTH MARKET ANALYSIS

The United States holds 95.20% of companion animal health in North America. The United States represents the single largest country-level market within the global companion animal health landscape, driven by a combination of structural, cultural, and regulatory factors that consistently support elevated healthcare spending for pets. The country benefits from one of the most extensive veterinary care networks in the world, encompassing general practice clinics, specialty and emergency hospitals, and academic veterinary medical centers engaged in cutting-edge research. Government agencies including the U.S. Department of Agriculture's Center for Veterinary Biologics and the FDA's Center for Veterinary Medicine maintain rigorous oversight frameworks that foster consumer confidence in approved health products. The rapid growth of the pet insurance sector has meaningfully expanded access to costly procedures, including orthopedic surgeries, oncology treatments, and advanced diagnostics. Consumer spending on companion animal health in the United States continues to grow year-on-year, fueled by humanization trends and a shift toward preventive care philosophies. Strong e-commerce channels for pet health products, alongside growing adoption of digital veterinary health platforms, further companion animal health market trends across the United States.

EUROPE COMPANION ANIMAL HEALTH MARKET ANALYSIS

Europe constitutes a significant and steadily expanding contributor to the global companion animal health market, supported by high pet ownership rates, progressive animal welfare legislation, and a well-established veterinary services sector. The United Kingdom, Germany, France, Italy, and Spain represent the largest national markets within the region, each characterized by dense veterinary clinic networks and sophisticated distribution systems for animal health products. European regulatory bodies, including the European Medicines Agency, apply stringent standards to veterinary pharmaceutical approvals, ensuring product quality and efficacy across member states. The growing adoption of preventive healthcare practices, including routine vaccination, parasite control, and dental care programs, reflects a cultural shift toward proactive animal health management. Rising elderly pet populations in several Western European countries are creating demand for geriatric care solutions, including mobility aids, pain management therapies, and specialized nutritional products.

ASIA-PACIFIC COMPANION ANIMAL HEALTH MARKET ANALYSIS

Asia-Pacific represents the fastest-growing regional market for companion animal health, driven by rapidly rising pet ownership in urbanizing economies including China, Japan, South Korea, India, and Australia. Expanding middle-class populations with increasing disposable incomes are embracing companion animals as lifestyle additions, fueling demand for veterinary services and health products. Urbanization and changing family structures, particularly the growing prevalence of single-person and childless households, have reinforced the emotional significance attached to pets across the region. Veterinary infrastructure is expanding rapidly, with significant investments in clinic networks, pharmaceutical distribution, and diagnostic laboratories in key markets. Government initiatives promoting animal disease surveillance and vaccination campaigns are improving formal healthcare penetration for companion animals.

LATIN AMERICA COMPANION ANIMAL HEALTH MARKET ANALYSIS

Latin America represents an emerging growth opportunity within the global companion animal health market, with Brazil and Mexico serving as the primary drivers of regional demand. Rising pet ownership rates, particularly in urban centers, and growing awareness of animal welfare standards are elevating healthcare spending for companion animals across the region. Expanding middle-class segments are increasingly adopting preventive veterinary care practices, including routine vaccinations and parasite management. The rollout of regional veterinary hospital chains and improved pharmaceutical distribution networks is broadening access to quality health products.

MIDDLE EAST AND AFRICA COMPANION ANIMAL HEALTH MARKET ANALYSIS

The Middle East and Africa region represents an emerging and gradually evolving segment within the companion animal health market, driven by rising urbanization, increasing pet adoption in metropolitan areas, and growing awareness of formal veterinary care. The Gulf Cooperation Council countries, particularly the United Arab Emirates and Saudi Arabia, are demonstrating the strongest demand growth, supported by affluent urban populations and a cultural shift toward pet ownership. Government initiatives across several African nations to control zoonotic diseases are indirectly stimulating investment in companion animal health infrastructure.

COMPETITIVE LANDSCAPE:

The global companion animal health market is characterized by a moderately consolidated competitive profile, with various multinational corporations dominating the market along with a significant number of mid-size companies that specialize in the field of animal health. The major companies in the field continue to invest heavily in research and development activities to enhance their product offerings in the fields of pharmaceuticals, vaccines, and diagnostics, among others. Mergers and acquisitions, partnerships, and collaborations have been significant mechanisms adopted by companies to compete with their peers in the field of animal health products. The various challenges faced by the companies, including the high cost of clinical trials for the development of novel biological products, the high cost of generic products, and the high cost of complying with various regulations in various markets, have been influencing the overall competitive dynamics of the market. The companies are also focusing on the development of precision medicine platforms, data-based disease management platforms, and direct-to-consumer digital initiatives to compete with their peers in the field of animal health products. Partnerships between research institutions and contract development organizations have been driving the overall innovation-based competition in the field of animal health products.

The report provides a comprehensive analysis of the competitive landscape in the companion animal health market with detailed profiles of all major companies, including:

• Agrolabo S.p.A.
• Boehringer Ingelheim International GmbH
• Ceva Sante Animale
• Dechra
• Elanco
• Greencross Vets
• IDEXX Laboratories Inc.
• Indian Immunologicals Ltd.
• Norbrook
• Vetoquinol
• Virbac
• Zoetis Services LLC

KEY QUESTIONS ANSWERED IN THIS REPORT

1. How big is the companion animal health market?

2. What is the future outlook of the companion animal health market?

3. What are the key factors driving the companion animal health market?

4. Which region accounts for the largest companion animal health market share?

5. Which are the leading companies in the global companion animal health market?

Table of Contents

1 Preface

2 Scope and Methodology

• 2.1 Objectives of the Study
• 2.2 Stakeholders
• 2.3 Data Sources
  • 2.3.1 Primary Sources
  • 2.3.2 Secondary Sources
• 2.4 Market Estimation
  • 2.4.1 Bottom-Up Approach
  • 2.4.2 Top-Down Approach
• 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

• 4.1 Overview
• 4.2 Key Industry Trends

5 Global Companion Animal Health Market

• 5.1 Market Overview
• 5.2 Market Performance
• 5.3 Impact of COVID-19
• 5.4 Market Forecast

6 Market Breakup by Animal Type

• 6.1 Dogs
  • 6.1.1 Market Trends
  • 6.1.2 Market Forecast
• 6.2 Cats
  • 6.2.1 Market Trends
  • 6.2.2 Market Forecast
• 6.3 Equine
  • 6.3.1 Market Trends
  • 6.3.2 Market Forecast
• 6.4 Others
  • 6.4.1 Market Trends
  • 6.4.2 Market Forecast

7 Market Breakup by Product

• 7.1 Vaccines
  • 7.1.1 Market Trends
  • 7.1.2 Market Forecast
• 7.2 Pharmaceuticals
  • 7.2.1 Market Trends
  • 7.2.2 Market Forecast
• 7.3 Feed Additives
  • 7.3.1 Market Trends
  • 7.3.2 Market Forecast
• 7.4 Diagnostics
  • 7.4.1 Market Trends
  • 7.4.2 Market Forecast
• 7.5 Others
  • 7.5.1 Market Trends
  • 7.5.2 Market Forecast

8 Market Breakup by End User

• 8.1 Point-of-care Testing/In-house Testing
  • 8.1.1 Market Trends
  • 8.1.2 Market Forecast
• 8.2 Veterinary Hospitals and Clinics
  • 8.2.1 Market Trends
  • 8.2.2 Market Forecast
• 8.3 Others
  • 8.3.1 Market Trends
  • 8.3.2 Market Forecast

9 Market Breakup by Region

• 9.1 North America
  • 9.1.1 United States
    • 9.1.1.1 Market Trends
    • 9.1.1.2 Market Forecast
  • 9.1.2 Canada
    • 9.1.2.1 Market Trends
    • 9.1.2.2 Market Forecast
• 9.2 Asia-Pacific
  • 9.2.1 China
    • 9.2.1.1 Market Trends
    • 9.2.1.2 Market Forecast
  • 9.2.2 Japan
    • 9.2.2.1 Market Trends
    • 9.2.2.2 Market Forecast
  • 9.2.3 India
    • 9.2.3.1 Market Trends
    • 9.2.3.2 Market Forecast
  • 9.2.4 South Korea
    • 9.2.4.1 Market Trends
    • 9.2.4.2 Market Forecast
  • 9.2.5 Australia
    • 9.2.5.1 Market Trends
    • 9.2.5.2 Market Forecast
  • 9.2.6 Indonesia
    • 9.2.6.1 Market Trends
    • 9.2.6.2 Market Forecast
  • 9.2.7 Others
    • 9.2.7.1 Market Trends
    • 9.2.7.2 Market Forecast
• 9.3 Europe
  • 9.3.1 Germany
    • 9.3.1.1 Market Trends
    • 9.3.1.2 Market Forecast
  • 9.3.2 France
    • 9.3.2.1 Market Trends
    • 9.3.2.2 Market Forecast
  • 9.3.3 United Kingdom
    • 9.3.3.1 Market Trends
    • 9.3.3.2 Market Forecast
  • 9.3.4 Italy
    • 9.3.4.1 Market Trends
    • 9.3.4.2 Market Forecast
  • 9.3.5 Spain
    • 9.3.5.1 Market Trends
    • 9.3.5.2 Market Forecast
  • 9.3.6 Russia
    • 9.3.6.1 Market Trends
    • 9.3.6.2 Market Forecast
  • 9.3.7 Others
    • 9.3.7.1 Market Trends
    • 9.3.7.2 Market Forecast
• 9.4 Latin America
  • 9.4.1 Brazil
    • 9.4.1.1 Market Trends
    • 9.4.1.2 Market Forecast
  • 9.4.2 Mexico
    • 9.4.2.1 Market Trends
    • 9.4.2.2 Market Forecast
  • 9.4.3 Others
    • 9.4.3.1 Market Trends
    • 9.4.3.2 Market Forecast
• 9.5 Middle East and Africa
  • 9.5.1 Market Trends
  • 9.5.2 Market Breakup by Country
  • 9.5.3 Market Forecast

10 SWOT Analysis

• 10.1 Overview
• 10.2 Strengths
• 10.3 Weaknesses
• 10.4 Opportunities
• 10.5 Threats

11 Value Chain Analysis

12 Porters Five Forces Analysis

• 12.1 Overview
• 12.2 Bargaining Power of Buyers
• 12.3 Bargaining Power of Suppliers
• 12.4 Degree of Competition
• 12.5 Threat of New Entrants
• 12.6 Threat of Substitutes

13 Price Analysis

14 Competitive Landscape

• 14.1 Market Structure
• 14.2 Key Players
• 14.3 Profiles of Key Players
  • 14.3.1 Agrolabo S.p.A.
    • 14.3.1.1 Company Overview
    • 14.3.1.2 Product Portfolio
  • 14.3.2 Boehringer Ingelheim International GmbH
    • 14.3.2.1 Company Overview
    • 14.3.2.2 Product Portfolio
  • 14.3.3 Ceva Sante Animale
    • 14.3.3.1 Company Overview
    • 14.3.3.2 Product Portfolio
  • 14.3.4 Dechra
    • 14.3.4.1 Company Overview
    • 14.3.4.2 Product Portfolio
    • 14.3.4.3 Financials
  • 14.3.5 Elanco
    • 14.3.5.1 Company Overview
    • 14.3.5.2 Product Portfolio
    • 14.3.5.3 Financials
  • 14.3.6 Greencross Vets
    • 14.3.6.1 Company Overview
    • 14.3.6.2 Product Portfolio
    • 14.3.6.3 Financials
    • 14.3.6.4 SWOT Analysis
  • 14.3.7 IDEXX Laboratories, Inc.
    • 14.3.7.1 Company Overview
    • 14.3.7.2 Product Portfolio
    • 14.3.7.3 Financials
    • 14.3.7.4 SWOT Analysis
  • 14.3.8 Indian Immunologicals Ltd.
    • 14.3.8.1 Company Overview
    • 14.3.8.2 Product Portfolio
  • 14.3.9 Norbrook
    • 14.3.9.1 Company Overview
    • 14.3.9.2 Product Portfolio
  • 14.3.10 Vetoquinol
    • 14.3.10.1 Company Overview
    • 14.3.10.2 Product Portfolio
    • 14.3.10.3 Financials
  • 14.3.11 Virbac
    • 14.3.11.1 Company Overview
    • 14.3.11.2 Product Portfolio
    • 14.3.11.3 Financials
    • 14.3.11.4 SWOT Analysis
  • 14.3.12 Zoetis Services LLC
    • 14.3.12.1 Company Overview
    • 14.3.12.2 Product Portfolio
    • 14.3.12.3 Financials
    • 14.3.12.4 SWOT Analysis